Results 1 to 10 of about 731,189 (260)

Polycythemia Vera Revealed by Acute Myocardial Infarction: A Case Report [PDF]

Reports
Background and Clinical Significance: Polycythemia vera is a myeloproliferative neoplasm associated with a high thrombotic risk. Although this association is well recognized, acute coronary syndrome as the initial manifestation of polycythemia vera is ...
Jéni Quintal, Raquel Flores, Tatiana Duarte, Ana Santo António, Filipe Seixo   +4 more
doaj   +2 more sources

Current management strategies for polycythemia vera and essential thrombocythemia

Blood Reviews, 2020
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of cardiovascular events, a varying burden of symptoms, and an intrinsic risk of evolution to secondary forms of myelofibrosis and ...
Alessandro Maria Vannucchi, Paola Guglielmelli   +1 more
exaly   +2 more sources

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Blood, 2019
Prior studies have reported high response rates with recombinant interferon-α (rIFN-α) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
Abdulraheem Yacoub, Alessandro Maria Vannucchi, Murat Osman Arcasoy   +2 more
exaly   +2 more sources

Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.

PLoS ONE, 2020
The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis are hematopoietic stem cell disorders and share driver mutations that either directly activate the thrombopoietin receptor, MPL, or activate it ...
Jerry L Spivak, Akil Merchant, Donna M Williams, Ophelia Rogers, Wanke Zhao, Amy Duffield, Linda S Resar, Alison R Moliterno, Zhizhuang J Zhao   +8 more
doaj   +2 more sources

CO‐Rebreathing in Essential Thrombocythemia and Polycythemia Vera. A Revival of an Old Methodology to Improve Diagnosis and Phlebotomy Decisions [PDF]

Cancer Med
ABSTRACT The diagnostic landscape for the Philadelphia‐negative myeloproliferative neoplasms (MPNs), particularly in distinguishing Essential Thrombocythemia (ET) from Polycythemia Vera (PV), is compromised. The gold standard for diagnosing PV—measurement of red cell mass (RCM) by radioisotope dilution—has been largely abandoned, leading to widespread ...
Hasselbalch H, Larsen M, Løffler L, Andersen C, Davidsen I, Jensen M, Bechlund J, Kjær L, Skov V, Nielsen H, Lundby C.   +10 more
europepmc   +2 more sources

Givinostat: an emerging treatment for polycythemia vera

Expert Opinion on Investigational Drugs, 2020
Introduction Polycythemia vera (PV), a Philadelphia chromosome-negative myeloproliferative neoplasm, is characterized by panmyelosis, pancytosis, and a JAK2 mutation.
Helen T Chifotides, Prithviraj Bose, Srdan Verstovsek   +2 more
exaly   +2 more sources

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

Haematologica, 2020
We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2).
Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, Mads Emil Bjørn, Christen Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Dustin Andersen Patel, Lise Mette Rahbek Gjerdrum, Daniel El Fassi, Torben A. Kruse, Thomas Stauffer Larsen, Hans Torben Mourits-Andersen, Claus Henrik Nielsen, Christina Ellervik, Niels Pallisgaard, Mads Thomassen, Lasse Kjær, Vibe Skov, Hans Carl Hasselbalch   +19 more
doaj   +2 more sources

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

Haematologica, 2019
Although it is well known that myeloproliferative neoplasms occur in younger patients, few large cohorts of such patients have been reported. Thus, our knowledge about circumstances of diagnosis, outcome and treatment is limited, especially for children ...
Jean-Christophe Ianotto, Natalia Curto-Garcia, Marie Lauermanova, Deepti Radia, Jean-Jacques Kiladjian, Claire N. Harrison   +5 more
doaj   +2 more sources

The Effect of Polycythemia Vera on Pregnancy Complications. The Analysis of an American Population Database With Over 9 Million Deliveries. [PDF]

Eur J Haematol
ABSTRACT Objectives Polycythemia Vera (PV) is characterized by overproduction of erythrocytes, leading to a hypercoagulable state. Evidence regarding associations between PV and pregnancy outcomes is limited. The aim of our study was to provide robust evidence regarding the prevalence of pregnancy complications in women with PV.
Margolese N, Al-Rayes S, Ton-Leclerc S, Badeghiesh A, Baghlaf H, Dahan MH.   +5 more
europepmc   +2 more sources

Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2023
Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative neoplasm characterized by clonal erythrocytosis; other features include leukocytosis, thrombocytosis, splenomegaly, pruritus, constitutional symptoms, microcirculatory disturbances, and ...
A. Tefferi, T. Barbui
semanticscholar   +1 more source